Genmab — Maj 2025

[E_L]

Shicheng Guo
@ShihchengGuo
New from Stanford & Genmab: UniTox uses GPT-4o to extract drug-induced toxicities from 2,400+ FDA labels into a structured dataset. https://x.com/ShihchengGuo/status/1926138781318385917

[E_L]

a bit more on - Insourcing Cell-line Development Streamlines Antibody Biomanufacturing - https://www.genengnews.com/topics/bioprocessing/insourcing-cell-line-development-streamlines-antibody-biomanufacturing

[M_T_A]

@EL thank you so much.

[ProinvestorNEWS]

Genmabs fremtidige salg af epcoritamab https://proinvestor.com/boards/126539

[E_L]

GEN1057 moves expected completion dates a year earlier, never really know what it means; either recruitment is going superfast or patients can stay on the drug much shorter as anticipated... anyway, we'll know earlier https://clinicaltrials.gov/study/NCT06573294?tab=history&a=7&b=8#version-content-panel

[gentogen]

As the 1057 study is a small phase 1 FIH study the goal is not to look at long term data so in a sense only positive if they can reach conclusions a bit sooner, I guess

[gentogen]

It would be nice i their laser sharp focus for once would be positive...

[Sukkeralf]

Do we know if all patients have been enrolled?

[E_L]

probably
not yet; the status is still 'recruiting' and 2 recruitment centers were just added

[Solsen]

Abbvie arbejder med nye payloads med bedre virkning deres allerede godkendte EMRELIS (telisotuzumab vedotin-tllv). Nyt stof ABBV-
400 (Telisotuzumab adizutecan) er værd at følge https://news.abbvie.com/2025-05-27-AbbVie-Features-New-Data-Across-Difficult-to-Treat-Solid-Tumors-and-Blood-Cancers-at-ASCO-2025,-Highlighting-Breadth-and-Depth-of-its-Oncology-Portfolio

[Solsen]

Genmab arbejder med samme indikationer med acasunlimab og nok mere sammenligneligt med deres ADC stof fra Profound - GEN1286

[Solsen]

ABBV-400 stammer fra Immunogen købet til $10bn. ABBV-400 har DAR 6 og artiklen der er linket til nævner SAE som noget vi skal holde øje med https://www.oncologypipeline.com/apexonco/asco-2024-preview-jury-still-out-abbvies-cancer-push Husk at Elahere som også kommer fra nævnte køb også har problematiske SAE (2% fatale). Rina-S er konkurrent til Elahere. Sandelig spændende for Abbvie

[ProinvestorNEWS]

Maj Status: NVIDIA, toldsatser, Novo, Zealand Pharma, Gubra, Genmab, Embla Kort video: https://proinvestor.com/boards/126575

[LP90]

Godmorgen

[Helge_LarsenPI-redaktør]

Godmorgen

[Stroka]

God morgen

[bibob]

God morgen

[E_L]

great start of ASCO for Biontech, -5%, Sanofi, -6%, Regeneron, -18% and Summit -24%, dragging this disastrous sector down again

[Solsen]

Summets PD1 x EGFR bispecifik fejlede endpoint OS i fase 3 https://finance.yahoo.com/news/ivonescimab-plus-chemotherapy-demonstrates-statistically-100000274.html

[Solsen]

Det rammer også Biontech. Hvorvidt Regeneron også satser på denne bispecific er jeg ikke klar over. Men flere selskaber har sat store forventninger netop til dette.